Cargando…

Associations Between the Use of Renin–Angiotensin System Inhibitors and the Risks of Severe COVID-19 and Mortality in COVID-19 Patients With Hypertension: A Meta-Analysis of Observational Studies

Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) share a target receptor with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The use of ACEIs/ARBs may cause angiotensin-converting enzyme 2 receptor upregulation, facilitating the entry of SARS-C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dai, Xiao-Ce, An, Zhuo-Yu, Wang, Zi-Yang, Wang, Zi-Zhen, Wang, Yi-Ren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107232/ https://www.ncbi.nlm.nih.gov/pubmed/33981731 http://dx.doi.org/10.3389/fcvm.2021.609857

Ejemplares similares

Renin-Angiotensin-System Inhibitors Are Associated With Lower In-hospital Mortality in COVID-19 Patients Aged 80 and Older
por: Spannella, Francesco, et al.
Publicado: (2022)

COVID and the Renin-Angiotensin System: Are Hypertension or Its Treatments Deleterious?
por: Zores, Florian, et al.
Publicado: (2020)

Prospective meta-analysis protocol on randomised trials of renin–angiotensin system inhibitors in patients with COVID-19: an initiative of the International Society of Hypertension
por: Gnanenthiran, Sonali Rukshana, et al.
Publicado: (2021)

Sex differences in the renin-angiotensin-aldosterone system and its roles in hypertension, cardiovascular, and kidney diseases
por: Nwia, Sarah M., et al.
Publicado: (2023)

Mortality and Pre‐Hospitalization use of Renin‐Angiotensin System Inhibitors in Hypertensive COVID‐19 Patients
por: Chen, Chen, et al.
Publicado: (2020)

Renin–angiotensin system inhibitors and mortality in patients with COVID-19
por: Rossi, Luca, et al.
Publicado: (2020)

Renin–angiotensin system inhibitors reduce cardiovascular mortality in hypertensive patients with severe aortic stenosis undergoing transcatheter aortic valve implantation: insights from the EffecTAVI registry
por: Basile, Christian, et al.
Publicado: (2023)

Relation Between Renin–Angiotensin–Aldosterone System Inhibitors and COVID-19 Severity
por: Alhaddad, Mousa J, et al.
Publicado: (2022)

Impact of renin–angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study
por: Zhong, Yanjun, et al.
Publicado: (2020)

Renin-Angiotensin-Aldosterone System Blockers Are Not Associated With Coronavirus Disease 2019 (COVID-19) Hospitalization: Study of 1,439 UK Biobank Cases
por: Raisi-Estabragh, Zahra, et al.
Publicado: (2020)

Association of renin–angiotensin system inhibitors use with short- and long-term mortality in patients with aortic stenosis: A systematic review and meta-analysis
por: Guan, Yang, et al.
Publicado: (2023)

Renin-Angiotensin-Aldosterone Inhibitors and COVID-19
por: Benenson, Irina, et al.
Publicado: (2020)

Lack of Effects of Renin-Angiotensin-Aldosterone System Activity and Beta-Adrenoceptor Pathway Polymorphisms on the Response to Bisoprolol in Hypertension
por: Zeng, Weiwei, et al.
Publicado: (2022)

Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on the Inflammatory Response and Viral Clearance in COVID-19 Patients
por: Huang, Linna, et al.
Publicado: (2021)

Renin-Angiotensin System Blockade and Mortality in Patients With Hypertension and COVID-19 Infection
por: Salah, Husam M., et al.
Publicado: (2020)

Patients With Obesity-Related Hypertension Treated With Renin-Angiotensin-Aldosterone System Antagonists Exhibit Lower Mortality And Less Severe COVID-19: A Retrospective Study
por: Kamalumpundi, Vijayvardhan, et al.
Publicado: (2021)

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension
por: Meng, Juan, et al.
Publicado: (2020)

Outcomes of discontinuing renin-angiotensin system inhibitors: a study protocol for conducting systematic review and meta-analysis
por: Suzuki, Taihei, et al.
Publicado: (2023)

Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review
por: Mascolo, Annamaria, et al.
Publicado: (2020)

Impact of the withdrawal of renin-angiotensin-aldosterone inhibitors on mortality in COVID-19 patients
por: Caro-Codón, Juan, et al.
Publicado: (2022)

Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19
por: Jarcho, John A., et al.
Publicado: (2020)

Hypothesis for renin-angiotensin inhibitor mitigation of COVID-19
por: Sackin, Henry
Publicado: (2021)

Renin–Angiotensin–Aldosterone Inhibitors and COVID-19 Infection
por: Tsampasian, Vasiliki, et al.
Publicado: (2022)

Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients
por: Gori, Mauro, et al.
Publicado: (2022)

Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19
por: Kang, Si-Hyuck, et al.
Publicado: (2021)

Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19
por: Williams, Bryan, et al.
Publicado: (2020)

Renin-angiotensin system inhibitor is associated with the reduced risk of all-cause mortality in COVID-19 among patients with/without hypertension
por: Wang, Huai-yu, et al.
Publicado: (2021)

Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts
por: Mahajan, Kunal, et al.
Publicado: (2020)

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19
por: Vaduganathan, Muthiah, et al.
Publicado: (2020)

Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
por: Reynolds, Harmony R., et al.
Publicado: (2020)

Renin-angiotensin system inhibitors in hospitalised patients with COVID-19
por: Williams, Bryan
Publicado: (2021)

Impact of renin–angiotensin–aldosterone system inhibitors on COVID-19
por: Matsuzawa, Yasushi, et al.
Publicado: (2022)

Renin-angiotensin-aldosterone system inhibitors and the COVID-19 epidemic
por: Silva-Cardoso, José, et al.
Publicado: (2022)

Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors
por: Golpe, Rafael, et al.
Publicado: (2020)

Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors
por: Golpe, Rafael, et al.
Publicado: (2020)

Impact of RAAS Inhibitors on Clinical Outcome and Mortality in Patients With STEMI During the COVID-19 Era: A Multicenter Observational Study
por: Barbieri, Lucia, et al.
Publicado: (2021)

COVID-19 and the Renin-Angiotensin System
por: Malha, Line, et al.
Publicado: (2020)

Renin-Angiotensin System and Sex Differences in COVID-19: A Critical Assessment
por: Chappell, Mark C.
Publicado: (2023)

Hypertension and COVID-19: Ongoing Controversies
por: Tadic, Marijana, et al.
Publicado: (2021)

Renin–angiotensin–aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis
por: Ssentongo, Anna E, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pb3a72e5rl41vmtpi4a6m64r4g